Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Dr Reddy’s Laboratories ( (RDY) ).
On May 11, 2026, Dr. Reddy’s Laboratories’ Nomination, Governance and Compensation Committee approved a significant grant of employee stock options under its existing share-based compensation plans. The company granted 816,119 Indian stock options under the 2018 ESOP and 376,115 ADR-linked stock options under the 2007 ADR scheme, all priced at Rs 1,293.90 per option with 100% vesting scheduled at the end of three years, signaling continued use of equity incentives to retain and align employees with long-term shareholder interests.
Both schemes comply with SEBI’s Share Based Employee Benefits and Sweat Equity Regulations, 2021, and are administered by the board-level committee, underscoring governance oversight of equity compensation. The new grants, once vested and exercised, will modestly expand the company’s equity base and could slightly dilute earnings per share, while strengthening talent retention across domestic and international operations.
The most recent analyst rating on (RDY) stock is a Buy with a $16.90 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
Spark’s Take on RDY Stock
According to Spark, TipRanks’ AI Analyst, RDY is a Outperform.
The score is driven primarily by strong fundamentals (profitability, growth, and low leverage), tempered by weaker cash-flow conversion. Earnings-call takeaways are moderately positive due to pipeline progress and strong liquidity, but near-term margins and regulatory delays add risk. Technicals are neutral-to-soft and valuation is reasonable with a low dividend yield.
To see Spark’s full report on RDY stock, click here.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories is an India-based multinational pharmaceutical company focused on generic medicines, branded formulations, active pharmaceutical ingredients and biosimilars. The company serves global markets including India and the U.S., and its shares are listed on the NSE, BSE and NYSE, as well as traded on NSE IFSC through depository receipts.
Average Trading Volume: 2,349,001
Technical Sentiment Signal: Hold
Current Market Cap: $11.4B
Find detailed analytics on RDY stock on TipRanks’ Stock Analysis page.